Vaccine Task Force: Critical to improve clarity and transparency on evolving vaccine market

AstraZeneca vaccine consignment at Nadi Airport. Picture: SUPPLIED/FT FILE

The Task Force Committee on Vaccines, Therapeutics and Diagnostics for Developing Countries says it is critical to improve clarity and transparency around the evolving vaccine market, expected production volumes, delivery schedules, and pre-purchase options.

The Task Force – established by the heads of the International Monetary Fund, World Bank Group, World Health Organization and the World Trade Organization to identify and resolve finance and trade impediments to vaccine, diagnostics, therapeutic production and deliveries – called on COVID vaccine manufacturers to accelerate delivery to developing countries.

“We call on advanced economies to scale-up near-term deliveries to developing countries,” the Task Force stated

The Task Force also launched a new website that includes the first phase of a global database, and country dashboards on vaccines, therapeutics, and diagnostics to guide their work and advocacy.

The database and dashboards, which also build on the IMF-WHO COVID-19 Vaccine Supply Tracker, seek to focus international attention and mobilize action by illuminating specific gaps, not just

According to the statement issued by the Task Force in Geneva yesterday, as per the IMF staff’s US$50 billion proposal to end the pandemic, and in line with the priorities set out by WHO, WTO, IMF and the World Bank Group, more than US$35 billion in grant were needed with only one third of this financed to date.

“We welcome the recent announcement by COVAX and the World Bank to accelerate vaccine supplies for developing countries through a new financing mechanism.

“We also welcome the partnership between the World Bank and AVAT, noting that World Bank financing is now available to support the purchase and deployment of doses secured by both AVAT and COVAX.”

More Stories